Skip to main content
. 2022 Jun 17;101(24):e29252. doi: 10.1097/MD.0000000000029252

Figure 1.

Figure 1

Experimental design. Treatment stages and samples sizes. Two different backbone drugs (ABC/3TC and FCT/TDF) and three different third agents (NNRTI, IP, and INI) were used in the HAART-baseline stage of the treatment. Patients were followed 24 and 48 weeks after the treatment change to the dual-therapy. HAART = highly active antiretroviral therapy, ABC/3TC = Abacavir/lamivudine, FCT/3TC = Tenofovir/emtricitabine, IP = Protease inhibitor, INI = Integrase strand transfer inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor.